However, the precise underlying mechanism driving the relationship between CSPG4 and PD1 expression, as well as the prognosis associated with PD1 immunotherapy in patients with BLCA, warrants further investigation through fundamental experimental and clinical trial analyses. Here, CSPG4 is linked to bladder transitional cell carcinoma.